Pioglitazone attenuates cardiometabolic risk factors in non-diabetic patients with dyslipidemia

Objective: to determine the effect of pioglitazone on cardiometabolic risk factors in non-diabetic patients with dyslipidaemia. methods: this prospective,randomised clinical trial was conducted at sheikh zayed medical college and hospital,rahim yar khan,pakistan,from august to october 2016,and comprised non-diabetic patients with dyslipidaemia. they were randomly divided into three groups. first and second groups were given a daily dose of tab pioglitazone 30mg and gemfibrozil 600mg,respectively,while the third group served as the healthy control. body weight,body mass index and serum lipid profile were analysed pre- and post-treatment. spss 16 was used for data analysis. results: of the 135 participants,there were 45(33.3%) in each group. after 12 weeks' treatment,the pioglitazone group showed a highly significant reduction in body weight (83±10.5 to 76±13.5kg) and body mass index (27.7±4.4 to 25.5±6.4kg/m2) (p<0.01) compared to the gemfibrozil group. the pioglitazone group showed a significant improvement in serum lipid profile after 12 weeks (p<0.05) while the gemfibrozil group showed a highly significant improvement in serum lipid profile (p<0.01). conclusion: pioglitazone independently improved cardiometabolic risk factors,even in non-diabetics. © 2017,pakistan medical association. all rights reserved.